NASDAQ:CELC Celcuity (CELC) Stock Forecast, Price & News $11.11 +0.17 (+1.55%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$10.89▼$11.4250-Day Range$9.39▼$11.3152-Week Range$7.42▼$14.40Volume50,618 shsAverage Volume44,868 shsMarket Capitalization$240.98 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Celcuity MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish12.75% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$6,422 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.69) to ($2.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.08 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Celcuity. Previous Next 0.0 Short Interest Percentage of Shares Shorted12.75% of the float of Celcuity has been sold short.Short Interest Ratio / Days to CoverCelcuity has a short interest ratio ("days to cover") of 17.8, which indicates bearish sentiment.Change versus previous monthShort interest in Celcuity has recently increased by 171.36%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCelcuity does not currently pay a dividend.Dividend GrowthCelcuity does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CELC. Previous Next 2.7 News and Social Media Coverage News SentimentCelcuity has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Celcuity this week, compared to 1 article on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Celcuity insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,422.00 in company stock.Percentage Held by Insiders24.29% of the stock of Celcuity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.05% of the stock of Celcuity is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Celcuity are expected to grow in the coming year, from ($2.69) to ($2.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Celcuity is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Celcuity is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCelcuity has a P/B Ratio of 1.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Celcuity (NASDAQ:CELC) StockCelcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.Read More Receive CELC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celcuity and its competitors with MarketBeat's FREE daily newsletter. Email Address CELC Stock News HeadlinesMay 24, 2023 | finance.yahoo.comInsiders of Celcuity Getting Good Value On Their US$1.6m InvestmentMay 16, 2023 | msn.comNeedham Reiterates Celcuity (CELC) Buy RecommendationJune 10, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 16, 2023 | finance.yahoo.comQ1 2023 Celcuity Inc Earnings CallMay 15, 2023 | finance.yahoo.comCelcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate UpdatesMay 15, 2023 | markets.businessinsider.comCraig-Hallum Keeps Their Buy Rating on Celcuity (CELC)May 14, 2023 | americanbankingnews.comCelcuity (CELC) Scheduled to Post Earnings on MondayMay 13, 2023 | marketwatch.comCelcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naive Patients at the 2023 ESMO Breast Cancer Annual CongressJune 10, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 12, 2023 | msn.comA Preview Of Celcuity's EarningsMay 12, 2023 | msn.comCelcuity gedatolisib combo shows promise in phase 1b trial in breast cancer patientsMay 8, 2023 | finance.yahoo.comCelcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference CallMay 8, 2023 | finance.yahoo.comCelcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual CongressApril 22, 2023 | americanbankingnews.comAnalyzing Celcuity (NASDAQ:CELC) & Aclarion (NASDAQ:ACON)April 18, 2023 | finance.yahoo.comCelcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023April 12, 2023 | finanznachrichten.deCelcuity Inc.: Celcuity to Participate in 22nd Annual Needham Virtual Healthcare ConferenceApril 12, 2023 | finance.yahoo.comCelcuity to Participate in 22nd Annual Needham Virtual Healthcare ConferenceMarch 27, 2023 | insidermonkey.comCelcuity Inc. (NASDAQ:CELC) Q4 2022 Earnings Call TranscriptMarch 26, 2023 | markets.businessinsider.comCraig-Hallum Remains a Buy on Celcuity (CELC)March 26, 2023 | markets.businessinsider.comCraig-Hallum Initiates a Buy Rating on Celcuity (CELC)March 24, 2023 | finance.yahoo.comQ4 2022 Celcuity Inc Earnings CallMarch 23, 2023 | finance.yahoo.comCelcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateMarch 16, 2023 | finance.yahoo.comCelcuity Inc. Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference CallMarch 15, 2023 | finance.yahoo.comCelcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023March 1, 2023 | finance.yahoo.comCelcuity to Participate in Cowen's 43rd Annual Health Care ConferenceFebruary 17, 2023 | finance.yahoo.comWhile institutions own 25% of Celcuity Inc. (NASDAQ:CELC), individual investors are its largest shareholders with 58% ownershipFebruary 16, 2023 | finance.yahoo.comCelcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers SymposiumSee More Headlines CELC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CELC Company Calendar Last Earnings3/23/2023Today6/10/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CELC CUSIPN/A CIK1603454 Webwww.celcuity.com Phone(763) 392-0767FaxN/AEmployees39Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-50.18% Return on Assets-37.12% Debt Debt-to-Equity Ratio0.29 Current Ratio28.26 Quick Ratio28.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.17 per share Price / Book1.80Miscellaneous Outstanding Shares21,690,000Free Float16,421,000Market Cap$240.98 million OptionableNot Optionable Beta0.60 Key ExecutivesBrian F. SullivanChairman & Chief Executive OfficerVicky HahneChief Financial OfficerLance G. LaingSecretary, Director & Chief Science OfficerArthur P. DeCillisChief Medical OfficerSheri SmithHead-Clinical OperationsKey CompetitorsHH&L AcquisitionNYSE:HHLAInvitaeNYSE:NVTAPersonalisNASDAQ:PSNLEnzo BiochemNYSE:ENZSera PrognosticsNASDAQ:SERAView All CompetitorsInsiders & InstitutionsRichard E BullerSold 100 sharesTotal: $1,050.00 ($10.50/share)Richard E BullerSold 250 sharesTotal: $2,462.50 ($9.85/share)Geode Capital Management LLCBought 61,152 shares on 5/16/2023Ownership: 0.613%Jane Street Group LLCBought 26,258 shares on 5/16/2023Ownership: 0.121%Susquehanna International Group LLPBought 10,100 shares on 5/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions CELC Stock - Frequently Asked Questions How have CELC shares performed in 2023? Celcuity's stock was trading at $14.01 at the start of the year. Since then, CELC stock has decreased by 20.7% and is now trading at $11.11. View the best growth stocks for 2023 here. When is Celcuity's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our CELC earnings forecast. How were Celcuity's earnings last quarter? Celcuity Inc. (NASDAQ:CELC) posted its quarterly earnings data on Thursday, March, 23rd. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.54) by $0.15. What other stocks do shareholders of Celcuity own? Based on aggregate information from My MarketBeat watchlists, some companies that other Celcuity investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Evoke Pharma (EVOK), Amicus Therapeutics (FOLD), Allena Pharmaceuticals (ALNA), Ampio Pharmaceuticals (AMPE), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA) and Ovid Therapeutics (OVID). When did Celcuity IPO? (CELC) raised $18 million in an initial public offering on Wednesday, September 20th 2017. The company issued 2,000,000 shares at $8.00-$10.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO. What is Celcuity's stock symbol? Celcuity trades on the NASDAQ under the ticker symbol "CELC." Who are Celcuity's major shareholders? Celcuity's stock is owned by a variety of retail and institutional investors. Top institutional investors include Commodore Capital LP (6.41%), Geode Capital Management LLC (0.61%), BlackRock Inc. (0.60%), Jacob Asset Management of New York LLC (0.31%), Citigroup Inc. (0.15%) and Renaissance Technologies LLC (0.13%). Insiders that own company stock include Brian F Sullivan, Richard E Buller and Richard Nigon. View institutional ownership trends. How do I buy shares of Celcuity? Shares of CELC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Celcuity's stock price today? One share of CELC stock can currently be purchased for approximately $11.11. How much money does Celcuity make? Celcuity (NASDAQ:CELC) has a market capitalization of $240.98 million. The company earns $-40,370,000.00 in net income (profit) each year or ($2.66) on an earnings per share basis. How can I contact Celcuity? Celcuity's mailing address is 16305 36TH AVENUE NORTH SUITE 100, MINNEAPOLIS MN, 55446. The official website for the company is www.celcuity.com. The company can be reached via phone at (763) 392-0767. This page (NASDAQ:CELC) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celcuity Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.